Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia

This study explored the relative efficacy of ibrutinib versus previous standard-of-care treatments in relapsed/refractory patients with chronic lymphocytic leukaemia (CLL), using multivariate regression modelling to adjust for baseline prognostic factors. Individual patient data were collected from...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Ann Hematol
Hlavní autoři: Hansson, Lotta, Asklid, Anna, Diels, Joris, Eketorp-Sylvan, Sandra, Repits, Johanna, Søltoft, Frans, Jäger, Ulrich, Österborg, Anders
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer Berlin Heidelberg 2017
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5569664/
https://ncbi.nlm.nih.gov/pubmed/28762081
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-017-3061-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky